Publication at Faculty of Medicine in Pilsen |
2023
Abstract
Prophylaxis of phlebothrombosis in oncology patients is an important topic with regard to the risks of morbidity and mortality. A relatively clear position on prophylaxis is given for patients hospitalized with malignancy and with limited mobility, in whom thromboprophylaxis with LMWH or fondaparinux (if creatinine clearance is >= 30 ml/min) or heparin is recommended.
In the current edition of the Czech Oncology Society guidelines book, this basic recommendation is slightly expanded - pharmacological thromboprophylaxis is recommended for hospitalized patients with active malignancy and acute internal disease or limited mobility, if they are not bleeding or have other contraindications.